Foundayo earns FDA priority

Eli Lilly’s Foundayo reached the market on April 1 after the Food and Drug Administration cleared it in 50 days under the agency’s National Priority Voucher pilot. (fda.gov) Foundayo is the brand name for orforglipron, a once-daily glucagon-like peptide-1 pill for adults with obesity, or overweight plus at least one weight-related condition. Lilly said it is the only approved GLP-1 weight-loss pill that can be taken any time of day without food or water restrictions. (lilly.com) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and slows stomach emptying. Most obesity drugs in that class have been injections, which is why an oral version has drawn attention from doctors, patients, and insurers. (fda.gov) The fast-track piece is unusual on its own. The Food and Drug Administration said Foundayo was the fifth approval under the Commissioner’s National Priority Voucher program, the first new molecular entity approved through it, and the fastest approval of a new molecular entity since 2002. (fda.gov) That voucher program, launched in June 2025, is designed to cut review times from the usual 10 to 12 months to about one to two months for products the agency says meet national health priorities. The Food and Drug Administration has said the process uses a cross-disciplinary “tumor board” style review model. (fda.gov) Lilly’s approval came with a second story attached: the Food and Drug Administration asked the company to collect more post-approval safety data on heart events, liver injury, and severe gastrointestinal problems. Pharmaceutical Executive reported Lilly released updated analyses after that request. (pharmexec.com) CNBC reported on April 14 that the agency’s letter asked for more information on possible liver injury linked to Foundayo. Fierce Pharma, citing the same Food and Drug Administration document, said regulators also flagged “unexpected serious” risks that still needed closer follow-up. (cnbc.com) (fiercepharma.com) Lilly has pointed to trial results showing an average 27-pound weight loss at the highest dose in the ATTAIN-1 study, and it started shipping the drug on April 6 through LillyDirect and retail pharmacies. The company said commercial coverage can start at $25 a month and self-pay at $149 a month. (lilly.com 1) (lilly.com 2) Early demand has been brisk. Pharmaceutical Executive, citing IQVIA data first reported by Reuters, said Foundayo logged 1,390 prescriptions in its first week, based on two days of captured dispensing data ending April 10. (pharmexec.com) The next test is whether doctors and payers treat a fast-cleared pill with added safety follow-up as interchangeable with older obesity brands. For now, Foundayo has both advantages Lilly wanted in the launch — a simple daily pill and a head start from the Food and Drug Administration. (fda.gov) (pharmexec.com)